DiaMedica Therapeutics is a biopharmaceutical company which engages in the development of treatments for neurological and kidney diseases. The Company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia.